The data also suggests that the inhibition of ERK1/2 phosphorylation with single treatments and its enhanced inhibition under the combination conditions suggests a potential impact of the treatments on colon cancer cell proliferation. The gene discussed is MAPK3; the disease is colonic neoplasm.